PBD Dimer Antibody Conjugates Self-Immolative Linker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates face challenges in achieving maximal efficacy with minimal toxicity, particularly in selectively delivering cytotoxic agents to tumor cells while avoiding normal cells, and in maintaining stability and specificity during intracellular delivery.
Innovation Solution
Development of pyrrolobenzodiazepine (PBD) dimer antibody conjugates with a self-immolative linker system that connects to the N10 position of PBD compounds, allowing for controlled release of active PBD units within cells, thereby maintaining cytotoxic effects and avoiding linker-induced reactivity issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibody-drug conjugates are used, then cytotoxic delivery to tumor cells is achieved, but stability and specificity during intracellular delivery deteriorate
Solution Approach 1:
The PBD dimer is segmented into two separate PBD units connected by a cleavable linker. The linker contains a self-immolative spacer that undergoes intramolecular cyclization to release the active PBD units intracellularly. This segmentation allows the conjugate to remain stable in circulation while becoming activated specifically inside tumor cells, resolving the contradiction between stability and selective cytotoxicity.
Solution Approach 2:
The self-immolative linker acts as an intermediary between the stable conjugate form and the active cytotoxic form. The linker contains a para-aminobenzyl alcohol spacer that undergoes intramolecular cyclization to form a stable five-membered ring, releasing the active PBD units. This intermediary mechanism ensures stability during delivery while enabling controlled activation inside tumor cells.
2Productivity
If PBD compounds are delivered to tumor cells, then cytotoxic effects are achieved, but linker-induced reactivity issues worsen
Solution Approach 1:
The linker design converts the potential harm of linker-induced reactivity into a beneficial self-immolative activation mechanism. The para-aminobenzyl alcohol spacer is designed to undergo intramolecular cyclization upon enzymatic cleavage, transforming the linker from a potential source of reactivity into a controlled activation switch that releases active PBD units specifically inside tumor cells.
3Object-affected harmful factors
If selective delivery to tumor cells is improved, then toxicity to normal cells is reduced, but manufacturing complexity increases
Solution Approach 1:
The self-immolative linker serves multiple functions simultaneously: it provides stable conjugation to the antibody, enables controlled intracellular activation through self-immolative cyclization, and prevents aggregation of the PBD units. This multi-functionality reduces the need for additional components, simplifying the overall conjugate structure while maintaining selective delivery and reducing toxicity to normal cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PBD dimer antibody conjugates demonstrate enhanced selective cytotoxicity and stability, ensuring targeted delivery and minimizing toxicity to normal cells, as evidenced by in vitro and xenograft model data, with the linker system facilitating effective intracellular activation and preventing aggregation.
Implementation Method 1
The linker is generally cleaved by action of an enzyme on the linker group, followed by an intramolecular cyclization of a self-immolative spacer to release the active PBD units.
Data Source
AI summary
The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.